Sarepta preliminary 2025 net product revenue $1.86B; ELEVIDYS $898.7M

Sarepta Therapeutics, Inc.

2025-FY EPS reported -$7.13 revenue$2,198,237,000

Total net product revenue Q4 $369.6M, full-year $1.86B; cash and investments $953.8M at year-end.
ELEVIDYS revenue Q4 $110.4M (impacted by flu and rescheduled infusions), full-year $898.7M.
PMO franchise revenue Q4 $259.2M, full-year $965.6M; described as durable.
CEO reconfirms ELEVIDYS annual sales floor of $500M; more detailed guidance deferred until initiatives evaluated.
Preliminary results unaudited; final Q4/FY 2025 results expected late February 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.